WGU D027 ADVANCED
PATHOPHARMACOLOGICAL FOUNDATIONS –
OBJECTIVE ASSESSMENT 2 QUESTIONS 1-200 AND
ANSWERS UPDATED 2026/2027 | DETAILED RATIONALES –
PRACTICE VERSION
INTRODUCTION
WGU D027, Advanced Pathopharmacological Foundations, is a graduate-level nursing course
focused on integrating advanced pathophysiology with pharmacologic principles and clinical
decision-making. WGU’s 2026 institutional catalog lists D027 as NURS 5204, a 3-CU course
within its graduate nursing curriculum.
This practice examination is designed for graduate nursing students who need to apply—not
simply memorize—pathophysiologic and pharmacologic concepts. The questions emphasize
clinical reasoning, medication mechanisms, adverse effects, contraindications, pharmacokinetic
and pharmacodynamic principles, organ-system disease processes, and interpretation of patient-
specific findings.
The scenarios are intentionally challenging and require the learner to connect laboratory
findings, disease mechanisms, medication effects, and expected clinical responses. Detailed
rationales explain both the correct answer and why the alternatives are less appropriate. Use the
bank as a structured review tool, then compare your reasoning against your course materials and
current evidence-based references. No practice bank can guarantee an assessment result, but
deliberate practice with difficult application questions can strengthen preparation for a high-
stakes objective assessment.
CORE DOMAINS TESTED
1. Cellular and Molecular Pathophysiology — Cellular injury, inflammation, apoptosis,
oxidative stress, receptors, and signaling.
2. Genetics and Pharmacogenomics — Genetic variation, inherited disorders, and
individualized medication response.
3. Pharmacokinetics — Absorption, distribution, metabolism, elimination, half-life, and
drug interactions.
4. Pharmacodynamics — Receptors, agonists, antagonists, dose-response relationships,
efficacy, and potency.
5. Cardiovascular Disorders — Hypertension, heart failure, ischemia, arrhythmias,
dyslipidemia, and anticoagulation.
, 6. Respiratory Disorders — Asthma, COPD, pneumonia, pulmonary embolism, and
respiratory failure.
7. Renal and Fluid/Electrolyte Disorders — AKI, CKD, acid-base disorders, sodium,
potassium, calcium, and volume abnormalities.
8. Endocrine and Metabolic Disorders — Diabetes, thyroid disorders, adrenal disorders,
and metabolic complications.
9. Neurologic Disorders — Seizures, Parkinson disease, stroke, multiple sclerosis, and
neuromuscular disorders.
10. Gastrointestinal and Hepatic Disorders — Liver disease, inflammatory bowel disease,
pancreatitis, and medication-related hepatic effects.
11. Hematologic Disorders — Anemias, coagulation disorders, thrombosis, and medication-
induced hematologic complications.
12. Immunologic and Inflammatory Disorders — Hypersensitivity, autoimmune disease,
cytokine-mediated inflammation, and immunomodulation.
13. Infectious Disease and Antimicrobial Therapy — Antimicrobial mechanisms,
resistance, adverse effects, and stewardship.
14. Oncology and Pharmacologic Toxicity — Cancer biology, chemotherapy effects, tumor
lysis, and targeted therapy principles.
15. Integrated Clinical Pharmacology — Medication selection based on comorbidities,
organ function, interactions, monitoring, and patient-specific risk.
QUESTIONS 1-100
Q1:
A 68-year-old patient with heart failure and chronic kidney disease is prescribed an ACE
inhibitor. Two weeks later, serum creatinine has increased from 1.4 to 1.8 mg/dL, while blood
pressure and potassium remain acceptable. Which mechanism best explains the expected initial
change in renal function?
A) Afferent arteriolar constriction caused by prostaglandin inhibition
B) Efferent arteriolar dilation reducing intraglomerular pressure
C) Increased renin-mediated afferent arteriolar constriction
D) Direct destruction of glomerular endothelial cells
Rationale: ACE inhibition decreases angiotensin II, producing preferential efferent arteriolar
dilation and reducing intraglomerular pressure. A small creatinine increase can therefore occur
after initiation. Option A describes NSAID-related effects. Option C is opposite to the expected
renin-angiotensin response. Option D is not the mechanism of ACE-inhibitor-associated
creatinine elevation.
Q2:
A patient with asthma begins a nonselective beta-blocker for migraine prevention and develops
wheezing shortly afterward. Which mechanism is most responsible?
,A) Increased parasympathetic acetylcholine release
B) Increased pulmonary surfactant production
C) Blockade of β2-mediated bronchodilation
D) Direct stimulation of airway muscarinic receptors
Rationale: β2 receptors promote bronchial smooth-muscle relaxation. Nonselective beta-
blockade can inhibit this response and precipitate bronchoconstriction. Options A and D do not
describe the principal medication effect, while option B is unrelated.
Q3:
A patient with cirrhosis receives a highly protein-bound medication. The patient develops a
stronger-than-expected pharmacologic response despite receiving the usual dose. Which
alteration most directly contributes?
A) Increased albumin synthesis
B) Increased renal filtration
C) Reduced albumin concentration increasing the unbound drug fraction
D) Increased first-pass hepatic metabolism
Rationale: Hypoalbuminemia increases the unbound fraction of highly protein-bound drugs,
potentially increasing pharmacologic activity. Cirrhosis does not increase albumin synthesis.
Renal filtration is not the primary mechanism, and hepatic metabolism is often reduced rather
than increased.
Q4:
A patient taking warfarin begins trimethoprim-sulfamethoxazole and returns with an
unexpectedly elevated INR. Which explanation is most appropriate?
A) Increased vitamin K synthesis
B) Increased warfarin renal clearance
C) Reduced warfarin metabolism combined with reduced vitamin K availability
D) Increased platelet production
Rationale: Trimethoprim-sulfamethoxazole can increase warfarin exposure through metabolic
inhibition and may reduce vitamin K-producing intestinal flora. The result can be an increased
INR and bleeding risk. Options A, B, and D would not explain the elevated anticoagulant effect.
Q5:
A patient with type 2 diabetes and established atherosclerotic cardiovascular disease requires
additional glucose-lowering therapy. Which class offers glucose reduction with cardiovascular
benefit in appropriate patients?
, A) Sulfonylurea
B) GLP-1 receptor agonist
C) Alpha-glucosidase inhibitor
D) Meglitinide
Rationale: GLP-1 receptor agonists improve glucose control and several agents in this class
provide cardiovascular risk reduction in appropriate patients. Sulfonylureas and meglitinides
primarily stimulate insulin release and may cause hypoglycemia. Alpha-glucosidase inhibitors
primarily delay carbohydrate absorption.
Q6:
A patient taking levothyroxine reports taking the medication every morning with calcium
carbonate. Thyroid-stimulating hormone remains elevated despite adherence. What is the most
likely explanation?
A) Calcium increases thyroid hormone synthesis
B) Calcium increases levothyroxine hepatic metabolism
C) Calcium decreases gastrointestinal absorption of levothyroxine
D) Calcium causes excessive conversion of T4 to T3
Rationale: Calcium can bind levothyroxine in the gastrointestinal tract and reduce absorption.
Separating administration is therefore important. The other choices do not explain the
interaction.
Q7:
A patient with chronic kidney disease receives an aminoglycoside for a serious infection. Which
parameter is most important for reducing toxicity?
A) Serum sodium
B) Renal function and drug concentration when indicated
C) Hemoglobin A1c
D) Thyroid-stimulating hormone
Rationale: Aminoglycosides are primarily eliminated by the kidneys and can cause
nephrotoxicity and ototoxicity. Renal function and, for selected regimens, therapeutic drug
monitoring are therefore important. The other laboratory values do not directly guide
aminoglycoside clearance.
Q8:
A patient develops profuse watery diarrhea after completing clindamycin therapy. Which
pathophysiologic process most likely explains the presentation?
PATHOPHARMACOLOGICAL FOUNDATIONS –
OBJECTIVE ASSESSMENT 2 QUESTIONS 1-200 AND
ANSWERS UPDATED 2026/2027 | DETAILED RATIONALES –
PRACTICE VERSION
INTRODUCTION
WGU D027, Advanced Pathopharmacological Foundations, is a graduate-level nursing course
focused on integrating advanced pathophysiology with pharmacologic principles and clinical
decision-making. WGU’s 2026 institutional catalog lists D027 as NURS 5204, a 3-CU course
within its graduate nursing curriculum.
This practice examination is designed for graduate nursing students who need to apply—not
simply memorize—pathophysiologic and pharmacologic concepts. The questions emphasize
clinical reasoning, medication mechanisms, adverse effects, contraindications, pharmacokinetic
and pharmacodynamic principles, organ-system disease processes, and interpretation of patient-
specific findings.
The scenarios are intentionally challenging and require the learner to connect laboratory
findings, disease mechanisms, medication effects, and expected clinical responses. Detailed
rationales explain both the correct answer and why the alternatives are less appropriate. Use the
bank as a structured review tool, then compare your reasoning against your course materials and
current evidence-based references. No practice bank can guarantee an assessment result, but
deliberate practice with difficult application questions can strengthen preparation for a high-
stakes objective assessment.
CORE DOMAINS TESTED
1. Cellular and Molecular Pathophysiology — Cellular injury, inflammation, apoptosis,
oxidative stress, receptors, and signaling.
2. Genetics and Pharmacogenomics — Genetic variation, inherited disorders, and
individualized medication response.
3. Pharmacokinetics — Absorption, distribution, metabolism, elimination, half-life, and
drug interactions.
4. Pharmacodynamics — Receptors, agonists, antagonists, dose-response relationships,
efficacy, and potency.
5. Cardiovascular Disorders — Hypertension, heart failure, ischemia, arrhythmias,
dyslipidemia, and anticoagulation.
, 6. Respiratory Disorders — Asthma, COPD, pneumonia, pulmonary embolism, and
respiratory failure.
7. Renal and Fluid/Electrolyte Disorders — AKI, CKD, acid-base disorders, sodium,
potassium, calcium, and volume abnormalities.
8. Endocrine and Metabolic Disorders — Diabetes, thyroid disorders, adrenal disorders,
and metabolic complications.
9. Neurologic Disorders — Seizures, Parkinson disease, stroke, multiple sclerosis, and
neuromuscular disorders.
10. Gastrointestinal and Hepatic Disorders — Liver disease, inflammatory bowel disease,
pancreatitis, and medication-related hepatic effects.
11. Hematologic Disorders — Anemias, coagulation disorders, thrombosis, and medication-
induced hematologic complications.
12. Immunologic and Inflammatory Disorders — Hypersensitivity, autoimmune disease,
cytokine-mediated inflammation, and immunomodulation.
13. Infectious Disease and Antimicrobial Therapy — Antimicrobial mechanisms,
resistance, adverse effects, and stewardship.
14. Oncology and Pharmacologic Toxicity — Cancer biology, chemotherapy effects, tumor
lysis, and targeted therapy principles.
15. Integrated Clinical Pharmacology — Medication selection based on comorbidities,
organ function, interactions, monitoring, and patient-specific risk.
QUESTIONS 1-100
Q1:
A 68-year-old patient with heart failure and chronic kidney disease is prescribed an ACE
inhibitor. Two weeks later, serum creatinine has increased from 1.4 to 1.8 mg/dL, while blood
pressure and potassium remain acceptable. Which mechanism best explains the expected initial
change in renal function?
A) Afferent arteriolar constriction caused by prostaglandin inhibition
B) Efferent arteriolar dilation reducing intraglomerular pressure
C) Increased renin-mediated afferent arteriolar constriction
D) Direct destruction of glomerular endothelial cells
Rationale: ACE inhibition decreases angiotensin II, producing preferential efferent arteriolar
dilation and reducing intraglomerular pressure. A small creatinine increase can therefore occur
after initiation. Option A describes NSAID-related effects. Option C is opposite to the expected
renin-angiotensin response. Option D is not the mechanism of ACE-inhibitor-associated
creatinine elevation.
Q2:
A patient with asthma begins a nonselective beta-blocker for migraine prevention and develops
wheezing shortly afterward. Which mechanism is most responsible?
,A) Increased parasympathetic acetylcholine release
B) Increased pulmonary surfactant production
C) Blockade of β2-mediated bronchodilation
D) Direct stimulation of airway muscarinic receptors
Rationale: β2 receptors promote bronchial smooth-muscle relaxation. Nonselective beta-
blockade can inhibit this response and precipitate bronchoconstriction. Options A and D do not
describe the principal medication effect, while option B is unrelated.
Q3:
A patient with cirrhosis receives a highly protein-bound medication. The patient develops a
stronger-than-expected pharmacologic response despite receiving the usual dose. Which
alteration most directly contributes?
A) Increased albumin synthesis
B) Increased renal filtration
C) Reduced albumin concentration increasing the unbound drug fraction
D) Increased first-pass hepatic metabolism
Rationale: Hypoalbuminemia increases the unbound fraction of highly protein-bound drugs,
potentially increasing pharmacologic activity. Cirrhosis does not increase albumin synthesis.
Renal filtration is not the primary mechanism, and hepatic metabolism is often reduced rather
than increased.
Q4:
A patient taking warfarin begins trimethoprim-sulfamethoxazole and returns with an
unexpectedly elevated INR. Which explanation is most appropriate?
A) Increased vitamin K synthesis
B) Increased warfarin renal clearance
C) Reduced warfarin metabolism combined with reduced vitamin K availability
D) Increased platelet production
Rationale: Trimethoprim-sulfamethoxazole can increase warfarin exposure through metabolic
inhibition and may reduce vitamin K-producing intestinal flora. The result can be an increased
INR and bleeding risk. Options A, B, and D would not explain the elevated anticoagulant effect.
Q5:
A patient with type 2 diabetes and established atherosclerotic cardiovascular disease requires
additional glucose-lowering therapy. Which class offers glucose reduction with cardiovascular
benefit in appropriate patients?
, A) Sulfonylurea
B) GLP-1 receptor agonist
C) Alpha-glucosidase inhibitor
D) Meglitinide
Rationale: GLP-1 receptor agonists improve glucose control and several agents in this class
provide cardiovascular risk reduction in appropriate patients. Sulfonylureas and meglitinides
primarily stimulate insulin release and may cause hypoglycemia. Alpha-glucosidase inhibitors
primarily delay carbohydrate absorption.
Q6:
A patient taking levothyroxine reports taking the medication every morning with calcium
carbonate. Thyroid-stimulating hormone remains elevated despite adherence. What is the most
likely explanation?
A) Calcium increases thyroid hormone synthesis
B) Calcium increases levothyroxine hepatic metabolism
C) Calcium decreases gastrointestinal absorption of levothyroxine
D) Calcium causes excessive conversion of T4 to T3
Rationale: Calcium can bind levothyroxine in the gastrointestinal tract and reduce absorption.
Separating administration is therefore important. The other choices do not explain the
interaction.
Q7:
A patient with chronic kidney disease receives an aminoglycoside for a serious infection. Which
parameter is most important for reducing toxicity?
A) Serum sodium
B) Renal function and drug concentration when indicated
C) Hemoglobin A1c
D) Thyroid-stimulating hormone
Rationale: Aminoglycosides are primarily eliminated by the kidneys and can cause
nephrotoxicity and ototoxicity. Renal function and, for selected regimens, therapeutic drug
monitoring are therefore important. The other laboratory values do not directly guide
aminoglycoside clearance.
Q8:
A patient develops profuse watery diarrhea after completing clindamycin therapy. Which
pathophysiologic process most likely explains the presentation?
